Acta Dermato-Venereologica (Jul 2021)
Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
Abstract
Abstract is missing (Short communication)